Bernard Pecoul, executive director of the non-profit research and development organization, said, "The fact that this Nobel Prize has been awarded to parasitologists who devoted their careers to the treatment of diseases that affect poor populations in low- and middle-income countries shows that research and development (R&D) can deliver concrete solutions of great importance to global public health."
Pecoul further added, "Two fixed-dose combination treatments that DNDi and partners delivered for malaria - ASAQ and ASMQ - were made possible thanks to artemisinin and addressed urgent needs. Unfortunately, such treatments are the exception rather than the rule."
Pecoul hoped the awards will inspire a new generation of researchers to pursue scientific careers in the field of neglected diseases. He said, "We also hope it will encourage greater public leadership in innovation and access to treatments for neglected patients. Today's award will go a long way in showing that innovation cannot be reserved only for those who can pay."